You can buy or sell CLBS and other stocks, options, ETFs, and crypto commission-free!
Caladrius Biosciences, Inc. Common Stock, also called Caladrius Biosciences, is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Read More Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Basking Ridge, New Jersey
52 Week High
52 Week Low
Simply Wall St21h
How Do Analysts See Caladrius Biosciences, Inc. (NASDAQ:CLBS) Performing In The Next Couple Of Years?
Caladrius Biosciences, Inc.’s (NASDAQ:CLBS) announced its latest earnings update in December 2018, which revealed that losses became smaller relative to the prior year’s level as a result of recent tailwinds Below is my commentary, albeit very simple and high-level, on how market analysts perceive Caladrius Biosciences’s earnings growth trajectory over the next few years and whether the future looks brighter. I will be looking at earnings excluding extraordinary items to exclude one-off activities to get a ...
Seeking AlphaMar 14
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q4 2018 Earnings Conference Call Transcript
Caladrius Biosciences, Inc. (NASDAQ:CLBS) Q4 2018 Earnings Conference Call March 14, 2019 4:30 PM ET Company Participants John Menditto - VP IR & Corporate Communications David Mazzo - President & CEO Joseph Talamo - SVP & CFO Conference Call Participants Pete Enderlin - MAZ Partners Operator Welcome to the Caladrius Biosciences Fourth Quarter and Full Year 2018 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode. Following management's prepar...
Yahoo FinanceMar 14
Caladrius Biosciences Reports 2018 Fourth Quarter and Year End Financial Results
Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, NJ / ACCESSWIRE / March 14, 2019 / Caladrius Biosciences, Inc. (CLBS) ("Caladrius" or the "Company"), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses and with a focus on select cardiovascular indications, announces financial results for the three and twelve months ended December 31, 2018. "20...
-$0.44 per share
-$0.36 per share